Viridian Therapeutics
Health Care · Immunology & Inflammation Therapeutics
$29Mtotal raised · 2 rounds on record
$27Mlatest round · Venture round · Sep 2020 · 6 yr ago
2backers · Broadview Ventures, Longitude Capital
240team · US Form 5500 (plan participants) · Dec 2025 · +64% in a year
Overview
Viridian Therapeutics is leveraging core expertise in antibody discovery to develop optimized treatments for rare autoimmune conditions.
Funding and backers
Total raised
$29M
2 rounds on record
Latest round
$27M
Venture round · Sep 2020 · 6 yr ago
Team
240
US Form 5500 (plan participants) · Dec 2025 · +64% in a year
Backers
2
Broadview Ventures, Longitude Capital
The money's age
Long since its last round
73 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2025
Team of 240 was 146 · US Form 5500 (plan participants)
Sep 17, 2020
Raised a round Venture round $27M · SEC Form D
Apr 24, 2020
Raised a round Venture round $2M · SEC Form D
2020
Founded
Tractionpublic signals, read monthly
Web presence
top 5%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Sep 2020 | $27M | — | SEC Form D |
| Venture round | Apr 2020 | $2M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Viridian Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Jonathan ViolinExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the…
Valora Therapeutics is developing AbLec™ multispecific antibodies and T-Lec™ T cell engagers — antibody-engineering platforms that decoy…
Diadem Biotherapeutics engineers first-in-class extracellular vesicles to target and treat cancer, chronic inflammatory and autoimmune…
Boomerang Medical is a bioelectronic medicine company targeting autoimmune diseases.
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology.
ImmuneSensor Therapeutics | Harnessing the innate immune system to treat inflammation, autoimmune disease and cancer.
Visa sponsorship
1 ▼ 67%
H-1B filings in 12 months
$258k
Median offered salary
0
Open roles in United States
Who they sponsor
Medical scientists
1
In the register as Viridian Therapeutics, Inc., Waltham, MA
Other sponsors in the same field
TrexBio 
Nektar 
InCellDx
Neutrolis
Alert me
US Department of Labor · latest filing Apr 29, 2026 · Visa details by country
People
Jonathan Violin
Executive Officer, Director
Peter Harwin
Director
Tomas Kiselak
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Broadview VenturesVia a fund
Longitude CapitalVia a fund
78 portfolio companies: Zenas BioPharma, Mobia Medical, Inc. and 76 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Viridian Therapeutics stock weighs Lumvoa uptake against losses
RBC lifted its Viridian target from USD 36.00 to USD 38.00 on September 22, 2026. Q2 EPS came in at minus USD 1.05.
Read more
Report
Analysts' Opinions Are Mixed on These Healthcare Stocks: CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN)
Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.
Read more
Report
Report
Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates
Read more
Report
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines ...
Read more
Report
Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?
Viridian Therapeutics (VRDN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read more
Report
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake
Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.
Read more
Report
Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts
Across the recent three months, 10 analysts have shared their insights on Viridian Therapeutics (NASDAQ:VRDN), expressing a variety of opinions spanning from bullish to bearish.In the table below, you'll find a summary of their recent ratings, ...
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Waltham
United States
HQ
Viridian Therapeutics, Inc.
Boulder
United States
Regional office
Colorado